3.

Responses to crizotinib treatment (median follow-up time: 6.91 months)

No.*	Age (year)	Gender	ALK-IHC	ALK-FISH	Response	ECOG PS	Therapy	Follow-up (month)	Discontinuation of crizotinib
*, 9 patients were still receiving crizotinib at the last follow-up date [median progression-free survival (mPFS) did not reach]. IHC, immunohistochemistry; ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization; ECOG PS, Eastern Cooperative Oncology Group performance score; F, female; M, male; CR, complete response; PR, partial response; PD, progressive disease; SD, stable disease.
P5	47	M	+	+	PD	1	First-line	2	Yes
P8	82	M	+	+	CR	1	First-line	10	No
P9	66	F	+	–	PR	1	First-line	3	Yes
P13	60	F	+	+	PR	1	First-line	13	No
P16	52	M	+	+	PR	0	Second-line	13	No
P20	45	M	+	–	SD	1	First-line	16	No
P21	50	M	+	+	SD	1	Third-line	6	No
P22	51	F	+	+	SD	3	First-line	4	No
P24	21	F	+	+	PR	3	First-line	2	No
P26	48	F	+	+	CR	1	First-line	6	No
P27	31	F	+	+	PR	1	First-line	1	No